---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-003900"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2026-01-15T23:59:59+00:00"
generated_at: "2026-05-16T10:06:00.692502+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ocugen: OCU410 shows 46% GA lesion reduction in Phase 2; Phase 1 EZ loss 60% slower

## Summary
- Phase 2 preliminary 12-month data (N=23) shows 46% GA lesion growth reduction vs control (p=0.015); medium dose 54% (p=0.02), high dose 36% (p=0.05).
- Subgroup with baseline ≥7.5 mm² (N=14) demonstrated 57% reduction in lesion size vs control.
- Phase 1 (N=7 evaluable) shows 60% slower ellipsoid zone loss in treated eyes vs untreated fellow eyes at 12 months.
- No OCU410-related serious adverse events reported across Phase 1 and Phase 2; no endophthalmitis, retinal detachment, or vasculitis.
- Company plans full Phase 2 data later Q1 2026, initiate Phase 3 in 2026, and BLA filing in 2028.

## SEC filing metadata
- accession: 0001104659-26-003900
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2026-01-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465926003900/0001104659-26-003900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465926003900/tm263269d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-003900
- JSON: https://secwatch.observer/filing/0001104659-26-003900.json
- Plain text: https://secwatch.observer/filing/0001104659-26-003900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.